Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
NCT03503331Phase 2Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Apr 2018
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carbon-11 Pittsburgh compound B in Alzheimer's disease (AD), sponsored by University of Alabama at Birmingham. Primary endpoint: Measurement of pathological beta-amyloid in the brain at 5 years. Started Apr 2018; status: recruiting.
02
Drugs
carbon-11 Pittsburgh compound B
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03503331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03503331.